PharmaEssentia
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Taiwan · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
2f-5 No. 3 Park St, Nangang District, Ta...Phone Number
+886 226557688Website
www.pharmaessentia.comRevenue
$215.4 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About PharmaEssentia
PharmaEssentia, founded in 2003 and based in Taipei, Taiwan, is a global biopharmaceutical company delivering therapeutic products for the treatment of human diseases.Explore more
PharmaEssentia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PharmaEssentia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
PharmaEssentia, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if PharmaEssentia had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at PharmaEssentia
Check if PharmaEssentia has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once PharmaEssentia has new funding data
Check out if PharmaEssentia is spiking on competitors!
Earning: See what the market has to say on PharmaEssentia recently announced quarterly report
Product Launch: Get notified when PharmaEssentia launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined PharmaEssentia as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
PharmaEssentia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PharmaEssentia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PharmaEssentia.
PharmaEssentia Tech Stack
A closer look at the technologies used by PharmaEssentia
See more technologies
Most Recent Scoops
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
PharmaEssentia News & Media
PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced it will be presenting clinical study results at the 2025 European Hematology Association (EHA) Congress, taking place June 12-15 in Milan, Italy. The company’s results from the Phase 3 SURPASS-PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced it will present results from the Phase 3 SURPASS-ET clinical trial in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in ChicPharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the latest National Comprehensive Cancer Network (NCCN) Guidelines (Version 1.2025, January 21, 2025) now highlight the substitution of ropeginterferon alfa-2b-njft (BESREMi®) for treatingICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)
VIENNA--(BUSINESS WIRE)-- #aophealth--Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. (“PharmaEssentia”) and AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in AOP Health’s favor. At the heart of the case were reciprocal claims for damages arising from a dispute regarding a licensing agreement between the parties. The product in dispute The conflict centers around ropeginterferon alfa-2b, a
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding PharmaEssentia
Sign Up For FreeTo access detailed company insights
PharmaEssentia, founded in 2003 and based in Taipei, Taiwan, is a global biopharmaceutical company delivering therapeutic products for the treatment of human diseases.... Read More
